2. Focus on Emerging Markets
*Please refer to next slide for graphical representation
Strategic Imperative:
• All companies have expressed keen interest in emerging markets
as growth drivers for them
• Viscira has immediate potential to drive growth in these areas as
well as within Europe and Asia Pac
– JC has pending presentations with GSK Australia, Japan and UK
– NiT has pending presentations at Allergan UK and at Berlin conference
Tactical Imperative for my business
• Merck has significant immunology presence with Remicade and
Simponi in Europe
– Allow me to represent Viscira at EULAR conference – Berlin, June 2012
• Merck’s CEO on emerging markets: “Merck’s Emerging Markets
(EM) business is anticipated to grow fasterh than underlying EM
pharmaceutical growth and is expected to account for over 25%
of Merck’s pharmaceutical and vaccine revenue in 2013.” –
Kenneth C. Frazier, President and CEO
-2-

3. PHARMERGING MARKETS
-3-